The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians

Revista de psiquiatrí́a y salud mental
Jose de Leon

Abstract

The literature on inducers in epilepsy and bipolar disorder is seriously contaminated by false negative findings. This is part i of a comprehensive review on antiepileptic drug (AED) inducers using both mechanistic pharmacological and evidence-based medicine to provide practical recommendations to neurologists and psychiatrists concerning how to control for them. Carbamazepine, phenobarbital and phenytoin, are clinically relevant AED inducers; correction factors were calculated for studied induced drugs. These correction factors are rough simplifications for orienting clinicians, since there is great variability in the population regarding inductive effects. As new information is published, the correction factors may need to be modified. Some of the correction factors are so high that the drugs (e.g., bupropion, quetiapine or lurasidone) should not co-prescribed with potent inducers. Clobazam, eslicarbazepine, felbamate, lamotrigine, oxcarbazepine, rufinamide, topiramate, vigabatrin and valproic acid are grouped as mild inducers which may (i)be inducers only in high doses; (ii)frequently combine with inhibitory properties; and (iii)take months to reach maximum effects or de-induction, definitively longer than the potent inducer...Continue Reading

References

Jan 1, 1990·Clinical Pharmacokinetics·R L NationR W Milne
Jan 1, 1990·European Journal of Clinical Pharmacology·P N PatsalosA A Elyas
Jan 1, 1989·British Journal of Clinical Pharmacology·E M Rimmer, A Richens
Apr 1, 1995·The American Journal of Psychiatry·L P Longo, C Salzman
Oct 1, 1994·Biological Psychiatry·P Finley, D Warner
Jun 1, 1994·Seizure : the Journal of the British Epilepsy Association·C D Ferrie, C P Panayiotopoulos
Jan 1, 1994·Epilepsia·P LloydW Dieterle
Aug 1, 1993·Clinical Pharmacokinetics·G Cheymol
Dec 31, 1997·The Journal of Clinical Psychiatry·J de Leon, J Bork
Mar 5, 1998·Therapeutic Drug Monitoring·M ChettyM A Seymour
Jun 2, 1998·The Annals of Pharmacotherapy·G D Anderson
May 22, 2002·Therapeutic Drug Monitoring·Theodor W MayUwe Jürgens
Aug 6, 2003·The International Journal of Neuropsychopharmacology·Jose de Leon
Sep 10, 2003·Clinical Pharmacokinetics·Theodor W MayBernhard Rambeck
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jose de Leon, Francisco J Diaz
Feb 6, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Jose de Leon
Feb 24, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stephanie R FaucetteEdward L LeCluyse
May 5, 2004·Psychosomatics·Gary H WynnKelly L Cozza
May 28, 2004·The Journal of Clinical Psychiatry·Gara CoffeyJose de Leon
Sep 10, 2004·Clinical Pharmacokinetics·Meir BialerStefan Schwabe
Dec 17, 2004·Journal of Clinical Pharmacology·Leslie CitromeSuresh Mallikaarjun
May 11, 2005·Psychosomatics·Jose de LeonKelly L Cozza
Jul 14, 2005·Journal of Clinical Psychopharmacology·Arne ReimersOlav Spigset
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jochen G W TheisJohn Ascher
Sep 1, 2005·Basic & Clinical Pharmacology & Toxicology·Mirko S FaberUwe Fuhr
Sep 15, 2005·Archives of Neurology·David WeintraubLawrence J Hirsch
Nov 25, 2005·European Journal of Clinical Pharmacology·M Strolin BenedettiF Tonner
May 13, 2006·The Journal of Clinical Investigation·Changcheng ZhouKenneth E Thummel

❮ Previous
Next ❯

Citations

Feb 16, 2016·Expert Opinion on Drug Metabolism & Toxicology·Edoardo SpinaJose de Leon
Nov 5, 2016·Journal of Clinical Psychopharmacology·Georgios SchoretsanitisMichael Paulzen
Dec 19, 2015·International Journal of Psychiatry in Medicine·Nitin Chopra, Jose de Leon
May 26, 2017·Journal of Pharmacy Practice·Ian R McGraneJose de Leon
Jan 20, 2018·International Journal of STD & AIDS·Manar M KandilChristopher A Schriever
May 20, 2018·Expert Review of Clinical Pharmacology·Georgios SchoretsanitisJose de Leon
Dec 22, 2017·Expert Opinion on Drug Metabolism & Toxicology·Srđan StefanovićMarko Folić
Feb 19, 2020·Journal of Pharmacy Practice·Ian R McGraneRobert C Munjal
Jun 11, 2020·Journal of Neural Transmission·Gudrun HefnerAnsgar Klimke
Sep 2, 2021·International Journal of Bipolar Disorders·Sean Bennett, Mujeeb U Shad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Expert Opinion on Drug Metabolism & Toxicology
Domenico ItalianoJose de Leon
Therapeutic Drug Monitoring
Houda HachadRené H Levy
Clinical Chemistry and Laboratory Medicine : CCLM
Hugo M NeelsWilly E Lambert
Pharmacy World & Science : PWS
D G Kasteleijn-Nolstlt Trenité, P M Edelbroek
© 2022 Meta ULC. All rights reserved